
--- Page 1 ---
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
ASSAY ONLY TEMPLATE
A. 510(k) Number:
k132418
B. Purpose for Submission:
Modification of a previously cleared device (k053165)
C. Measurand:
Sodium, Potassium, Chloride
D. Type of Test:
Ion Selective Electrode Potentiometry
E. Applicant:
Roche Diagnostics
F. Proprietary and Established Names:
cobas c 501 ISE Indirect Na, K, Cl for Gen. 2
G. Regulatory Information:
1. Regulation section:
21CFR 862.1665, Ion Specific Electrode, Sodium
21CFR 862.1600, Ion Specific Electrode, Potassium
21CFR 862.1170, Ion Specific Electrode, Chloride
2. Classification:
Class II
3. Product code:
JGS
CEM
CGZ
1

--- Page 2 ---
4. Panel:
Clinical Chemistry (75)
H. Intended Use:
1. Intended use(s):
See indication(s) for use below
2. Indication(s) for use:
The ISE module of the Roche/Hitachi systems is intended for the quantitative
determination of sodium, potassium, and chloride in serum, plasma, or urine using ion-
selective electrodes.
Sodium measurements are used in the diagnosis and treatment of aldosteronism
(excessive secretion of hormone aldosterone), diabetes insipidus (chronic excretion of
large amounts of dilute urine, accompanied by extreme thirst), adrenal hypertension,
Addison’s disease (caused by destruction of the adrenal glands), dehydration,
inappropriate antidiuretic hormone secretion, or other diseases involving electrolyte
imbalance. Potassium measurements are used to monitor electrolyte balance in the
diagnosis and treatment of disease conditions characterized by low or high blood
potassium levels. Chloride measurements are used in the diagnosis and treatment of
electrolyte and metabolic disorders such as cystic fibrosis and diabetic acidosis.
3. Special conditions for use statement(s):
For prescription use only.
4. Special instrument requirements:
cobas c 501
I. Device Description:
The main modification of the device is the ISE calibrator 3 (S3) was changed from serum
based to aqueous based and the concentrations of the Na, K, and Cl were made to be the
same as ISE calibrator 2 (S2). The following ISE calibrators, auxiliary reagents, and
electrodes are required to calibrate and calculate results for the ISE module and were used in
the performance studies of the cobas c 501 ISE system.
ISE Calibrators S1, S2, and S3:
· S1: ISE Standard Low (120 mmol/L Na+, 3 mmol/L K+, 80 mmol/L Cl-)
· S2: ISE Standard High (160 mmol/L Na+, 7 mmol/L K+, 120 mmol/L Cl-)
2

--- Page 3 ---
· S3: ISE Standard High (160 mmol/L Na+, 7 mmol/L K+, 120 mmol/L Cl-)
Auxiliary Reagents:
· ISE Reference Electrolyte (1 mol/L potassium chloride) provides a strong stable ion
reference potential in the reference electrode necessary for each ISE measurement.
· ISE Diluent (HEPES buffer: 10mmol/L, Triethanolamine: 7 mmol/L, preservative) is
used for sample dilution.
· ISE Internal Standard (HEPES buffer: 10mmol/L, Triethanolamine: 7 mmol/L, Sodium
Chloride: 3.06 mmol/L, Sodium acetate: 1.45 mmol/L, Potassium Chloride: 0.16 mmol/L,
preservative) is used for a baseline calibration which is performed once every ISE cycle.
· ISE Cleaning Solution: Sodium hydroxide solution (12%) is intended to clean the ion-
selective electrodes, vessel and tubing.
ISE Electrodes: Sodium Electrode, Potassium Electrode, Chloride Electrode, and Reference
Electrode
J. Substantial Equivalence Information:
1. Predicate device name(s):
cobas c 501 analyzer ISE
2. Predicate 510(k) number(s):
k053165
3. Comparison with predicate:
Similarities
Item Candidate device cobas c Predicate device
501 ISE Indirect Na, K, Cl cobas c 501 analyzer ISE
for Gen. 2 (k053165)
Intended Use The ISE module of the Same
Roche/Hitachi cobas c
system is intended for the
quantitative determination
of sodium, potassium and
chloride in serum, plasma or
urine using ion-selective
electrodes.
Measurement Principle ISE Potentiometry Same
Onboard storage 5-12˚C Same
temperature
Ion Selective Electrodes Potentiometric chloride, Same
potassium, sodium and
reference electrodes.
3

[Table 1 on page 3]
Similarities								
	Item			Candidate device cobas c			Predicate device	
				501 ISE Indirect Na, K, Cl			cobas c 501 analyzer ISE	
				for Gen. 2			(k053165)	
								
Intended Use			The ISE module of the
Roche/Hitachi cobas c
system is intended for the
quantitative determination
of sodium, potassium and
chloride in serum, plasma or
urine using ion-selective
electrodes.			Same		
Measurement Principle			ISE Potentiometry			Same		
Onboard storage
temperature			5-12˚C			Same		
Ion Selective Electrodes			Potentiometric chloride,
potassium, sodium and
reference electrodes.			Same		

--- Page 4 ---
Similarities
Item Candidate device cobas c Predicatedevice
501 ISE Indirect Na, K, Cl cobas c 501 analyzer ISE
for Gen. 2 (k053165)
Sample Dilution 1:31 Same
Reportable Range for Sodium: 80-180 mmol/L Same
Serum and Plasma Potassium: 1.5-10 mmol/L
Chloride: 60-140 mmol/L
Differences
Item Candidate device Predicate device
Standard 3 (High) ISE standard high (aqueous) S3 (serum based
Calibrator compensator)
Reportable Range for Sodium: 20-250 mmol/L Sodium: 10-250 mmol/L
Urine Potassium: 3-100 mmol/L Potassium: 1-100 mmol/L
Chloride: 20-250 mmol/L Chloride: 10-250 mmol/L
K. Standard/Guidance Document Referenced (if applicable):
CLSI EP5-A2: Evaluation of Precision of Clinical Chemistry Devices, Approved Guideline-
2nd Edition
CLSI EP6-A: Evaluation of the Linearity of Quantitative Measurement Procedures: A
Statistical Approach; Approved Guideline
CLSI EP17-A2: Evaluation of Detection Capability for Clinical Laboratory Measurement
Procedures; Approved Guideline-Second Edition.
L. Test Principle:
The cobas c 501 with and ISE module is an Ion-Selective Electrode (ISE) system for the
determination of sodium, potassium, and chloride in serum, plasma, and urine. An ISE
makes use of the unique properties of certain membrane materials to develop and electrical
potential (electromotive force, EMF) for the measurements of ions in solution. The electrode
has a selective membrane in contact with both the test solution and an intimal filling solution.
The internal filling solution contains the test ion at fixed concentration. Because of the
particular nature of the membrane, the test joins will closely associate with the membrane on
each side. The membrane EMF is determined by the difference in concentration of the test
ion in the test solution and the internal filling solution. The EMF develops according to the
Nernst equation for a specific ion in solution.
4

[Table 1 on page 4]
Similarities								
	Item			Candidate device cobas c			Predicatedevice	
				501 ISE Indirect Na, K, Cl			cobas c 501 analyzer ISE	
				for Gen. 2			(k053165)	
								
Sample Dilution			1:31			Same		
Reportable Range for
Serum and Plasma			Sodium: 80-180 mmol/L
Potassium: 1.5-10 mmol/L
Chloride: 60-140 mmol/L			Same		

[Table 2 on page 4]
Differences								
	Item			Candidate device			Predicate device	
Standard 3 (High)
Calibrator			ISE standard high (aqueous)			S3 (serum based
compensator)		
Reportable Range for
Urine			Sodium: 20-250 mmol/L
Potassium: 3-100 mmol/L
Chloride: 20-250 mmol/L			Sodium: 10-250 mmol/L
Potassium: 1-100 mmol/L
Chloride: 10-250 mmol/L		

--- Page 5 ---
M. Performance Characteristics (if/when applicable):
1. Analytical performance:
a. Precision/Reproducibility:
Precision studies for serum and urine applications of the cobasc501 ISE electrodes for
the measurement of Na, K, and Cl were performed using 1 analyzer, 1 site, l lot of
reagent, and 6 samples. The 6 samples used for the serum precision testing were
comprised of 4 human serum sample pools of varying concentrations (low, mid, mid-
low, and high) for each analyte; and Precinorm U and Precipath U controls. The 6
samples used for the urine precision testing were comprised of 4 human urine sample
pools of varying concentrations (low, mid, mid-low, and high) for each analyte; and
Liquichek Level 1 and Liquichek Level 2 controls. The within run precision study
was performed with 21 single determinations for each analyte. The intermediate
precision was performed over a period of 21 days, 2 runs per day, and 2 aliquots per
run for a total of 84 samples per analyte. The result summaries for the precision
studies are presented in the tables below:
Within Run Precision
Sodium (Serum)
Sample PNU PPU HS low HS med HS MDL HS high
Unit mmol/L mmol/L mmol/L mmol/L mmol/L mmol/L
n 21 21 21 21 21 21
Mean 125.6 147.5 84.4 121.3 131.7 177.2
SD 0.3 0.4 0.2 0.2 0.3 0.4
%CV 0.2 0.3 0.3 0.2 0.2 0.2
Sodium (Urine)
Sample Liq 1 Liq 2 HU low HU med HU MDL HU high
Unit mmol/L mmol/L mmol/L mmol/L mmol/L mmol/L
n 21 21 21 21 21 21
Mean 80.2 169.2 29.9 131.3 22.7 236.1
SD 0.2 0.2 0.3 0.2 0.3 0.2
%CV 0.2 0.2 0.3 0.2 0.3 0.2
Potassium (Serum)
Sample PNU PPU HS low HS med HS MDL HS high
Unit mmol/L mmol/L mmol/L mmol/L mmol/L mmol/L
n 21 21 21 21 21 21
Mean 3.58 6.78 1.62 4.99 2.64 9.49
SD 0.02 0.04 0.01 0.02 0.01 0.05
%CV 0.6 0.6 0.6 0.4 0.4 0.5
5

[Table 1 on page 5]
	Sample			PNU			PPU			HS low			HS med			HS MDL			HS high	
	Unit			mmol/L			mmol/L			mmol/L			mmol/L			mmol/L			mmol/L	
	n		21			21			21			21			21			21		
	Mean		125.6			147.5			84.4			121.3			131.7			177.2		
	SD		0.3			0.4			0.2			0.2			0.3			0.4		
	%CV		0.2			0.3			0.3			0.2			0.2			0.2		

[Table 2 on page 5]
	Sample			Liq 1			Liq 2			HU low			HU med			HU MDL			HU high	
	Unit			mmol/L			mmol/L			mmol/L			mmol/L			mmol/L			mmol/L	
	n		21			21			21			21			21			21		
	Mean		80.2			169.2			29.9			131.3			22.7			236.1		
	SD		0.2			0.2			0.3			0.2			0.3			0.2		
	%CV		0.2			0.2			0.3			0.2			0.3			0.2		

[Table 3 on page 5]
	Sample			PNU			PPU			HS low			HS med			HS MDL			HS high	
	Unit			mmol/L			mmol/L			mmol/L			mmol/L			mmol/L			mmol/L	
	n		21			21			21			21			21			21		
	Mean		3.58			6.78			1.62			4.99			2.64			9.49		
	SD		0.02			0.04			0.01			0.02			0.01			0.05		
	%CV		0.6			0.6			0.6			0.4			0.4			0.5		

--- Page 6 ---
Potassium (Urine)
Sample Liq 1 Liq 2 HU low HU med HU MDL HU high
Unit mmol/L mmol/L mmol/L mmol/L mmol/L mmol/L
n 21 21 21 21 21 21
Mean 31.7 70.6 5.25 51.90 15.3 89.80
SD 0.2 0.3 0.03 0.2 0.1 0.4
%CV 0.6 0.4 0.6 0.4 0.7 0.5
Chloride (Serum)
Sample PNU PPU HS low HS med HS MDL HS high
Unit mmol/L mmol/L mmol/L mmol/L mmol/L mmol/L
n 21 21 21 21 21 21
Mean 85.2 117.4 67.6 128.6 91.6 139.0
SD 0.3 0.4 0.2 0.3 0.3 0.4
%CV 0.4 0.3 0.2 0.2 0.4 0.3
Chloride (Urine)
Sample Liq 1 Liq 2 HU low HU med HU MDL HU high
Unit mmol/L mmol/L mmol/L mmol/L mmol/L mmol/L
n 21 21 21 21 21 21
Mean 95.2 195.4 25.0 130.6 23.4 242.9
SD 0.3 0.5 0.1 0.4 0.1 0.7
%CV 0.3 0.2 0.4 0.3 0.3 0.3
Total (Intermediate) Precision
Sodium (Serum)
Sample PNU PPU HS low HS med HS MDL HS high
Unit mmol/L mmol/L mmol/L mmol/L mmol/L mmol/L
n 84 84 84 84 84 84
Mean 126.0 148.2 84.8 121.4 131.6 176.7
SD 0.7 0.5 1.0 0.8 0.7 0.6
%CV 0.5 0.4 1.1 0.6 0.5 0.4
Sodium (Urine)
Sample Liq 1 Liq 2 HU low HU med HU MDL HU high
Unit mmol/L mmol/L mmol/L mmol/L mmol/L mmol/L
n 84 84 84 84 84 84
Mean 81.6 172.3 30.6 131.7 23.3 236.7
SD 1.3 2.6 0.9 0.6 0.9 1.3
%CV 1.6 1.5 3.0 0.5 3.8 0.6
6

[Table 1 on page 6]
	Sample			Liq 1			Liq 2			HU low			HU med			HU MDL			HU high	
	Unit			mmol/L			mmol/L			mmol/L			mmol/L			mmol/L			mmol/L	
	n		21			21			21			21			21			21		
	Mean		31.7			70.6			5.25			51.90			15.3			89.80		
	SD		0.2			0.3			0.03			0.2			0.1			0.4		
	%CV		0.6			0.4			0.6			0.4			0.7			0.5		

[Table 2 on page 6]
	Sample			PNU			PPU			HS low			HS med			HS MDL			HS high	
	Unit			mmol/L			mmol/L			mmol/L			mmol/L			mmol/L			mmol/L	
	n		21			21			21			21			21			21		
	Mean		85.2			117.4			67.6			128.6			91.6			139.0		
	SD		0.3			0.4			0.2			0.3			0.3			0.4		
	%CV		0.4			0.3			0.2			0.2			0.4			0.3		

[Table 3 on page 6]
	Sample			Liq 1			Liq 2			HU low			HU med			HU MDL			HU high	
	Unit			mmol/L			mmol/L			mmol/L			mmol/L			mmol/L			mmol/L	
	n		21			21			21			21			21			21		
	Mean		95.2			195.4			25.0			130.6			23.4			242.9		
	SD		0.3			0.5			0.1			0.4			0.1			0.7		
	%CV		0.3			0.2			0.4			0.3			0.3			0.3		

[Table 4 on page 6]
	Sample			PNU			PPU			HS low			HS med			HS MDL			HS high	
	Unit			mmol/L			mmol/L			mmol/L			mmol/L			mmol/L			mmol/L	
	n		84			84			84			84			84			84		
	Mean		126.0			148.2			84.8			121.4			131.6			176.7		
	SD		0.7			0.5			1.0			0.8			0.7			0.6		
	%CV		0.5			0.4			1.1			0.6			0.5			0.4		

[Table 5 on page 6]
	Sample			Liq 1			Liq 2			HU low			HU med			HU MDL			HU high	
	Unit			mmol/L			mmol/L			mmol/L			mmol/L			mmol/L			mmol/L	
	n		84			84			84			84			84			84		
	Mean		81.6			172.3			30.6			131.7			23.3			236.7		
	SD		1.3			2.6			0.9			0.6			0.9			1.3		
	%CV		1.6			1.5			3.0			0.5			3.8			0.6		

--- Page 7 ---
Potassium (Serum)
Sample PNU PPU HS low HS med HS MDL HS high
Unit mmol/L mmol/L mmol/L mmol/L mmol/L mmol/L
n 84 84 84 84 84 84
Mean 3.57 6.59 1.62 4.97 2.63 9.46
SD 0.04 0.05 0.03 0.04 0.07 0.07
%CV 1.0 0.7 1.6 0.8 0.7 1.0
Potassium (Urine)
Sample Liq 1 Liq 2 HU low HU med HU MDL HU high
Unit mmol/L mmol/L mmol/L mmol/L mmol/L mmol/L
n 84 84 84 84 84 84
Mean 31.5 70.6 5.2 52.1 15.4 90.3
SD 0.5 1.17 0.04 0.7 0.1 1.4
%CV 1.7 1.7 0.7 1.3 0.9 1.5
Chloride (Serum)
Sample PNU PPU HS low HS med HS MDL HS high
Unit mmol/L mmol/L mmol/L mmol/L mmol/L mmol/L
n 84 84 84 84 84 84
Mean 86.2 119.2 68.5 129.0 92.3 139.0
SD 0.5 0.5 0.6 0.6 0.5 0.6
%CV 0.6 0.4 0.8 0.5 0.6 0.4
Chloride (Urine)
Sample Liq 1 Liq 2 HU low HU med HU MDL HU high
Unit mmol/L mmol/L mmol/L mmol/L mmol/L mmol/L
n 84 84 84 84 84 84
Mean 97.5 198.2 25.8 131.4 24.3 243.4
SD 1.6 2.3 0.6 0.7 0.6 1.8
%CV 1.6 1.2 2.3 0.5 2.4 0.7
b. Linearity/assay reportable range:
Linearity studies were performed according to CLSI EP6-A. Dilution series of 11
concentrations were prepared using low and high human serum, plasma, and urine sample
pools for each of the analytes and tested in triplicate. Linear regression analysis was
done according to EP6-A. Linear regression summary results of the study are presented
in the table below:
7

[Table 1 on page 7]
	Sample			PNU			PPU			HS low			HS med			HS MDL			HS high	
	Unit			mmol/L			mmol/L			mmol/L			mmol/L			mmol/L			mmol/L	
	n		84			84			84			84			84			84		
	Mean		3.57			6.59			1.62			4.97			2.63			9.46		
	SD		0.04			0.05			0.03			0.04			0.07			0.07		
	%CV		1.0			0.7			1.6			0.8			0.7			1.0		

[Table 2 on page 7]
	Sample			Liq 1			Liq 2			HU low			HU med			HU MDL			HU high	
	Unit			mmol/L			mmol/L			mmol/L			mmol/L			mmol/L			mmol/L	
	n		84			84			84			84			84			84		
	Mean		31.5			70.6			5.2			52.1			15.4			90.3		
	SD		0.5			1.17			0.04			0.7			0.1			1.4		
	%CV		1.7			1.7			0.7			1.3			0.9			1.5		

[Table 3 on page 7]
	Sample			PNU			PPU			HS low			HS med			HS MDL			HS high	
	Unit			mmol/L			mmol/L			mmol/L			mmol/L			mmol/L			mmol/L	
	n		84			84			84			84			84			84		
	Mean		86.2			119.2			68.5			129.0			92.3			139.0		
	SD		0.5			0.5			0.6			0.6			0.5			0.6		
	%CV		0.6			0.4			0.8			0.5			0.6			0.4		

[Table 4 on page 7]
	Sample			Liq 1			Liq 2			HU low			HU med			HU MDL			HU high	
	Unit			mmol/L			mmol/L			mmol/L			mmol/L			mmol/L			mmol/L	
	n		84			84			84			84			84			84		
	Mean		97.5			198.2			25.8			131.4			24.3			243.4		
	SD		1.6			2.3			0.6			0.7			0.6			1.8		
	%CV		1.6			1.2			2.3			0.5			2.4			0.7		

--- Page 8 ---
Analyte Matrix Slope Intercept Range Tested
(mmol/L)
Sodium Serum 0.9804 2.7508 70-190
Sodium Plasma 1.0076 0.8378 70-185
Sodium Urine 1.0100 2.1287 15-250
Potassium Serum 0.9978 0.0437 1.5-11.0
Potassium Urine 0.9781 0.3260 3.0-110
Chloride Serum 1.0690 1.1321 60-145
Chloride Plasma 0.9788 3.4818 60-140
Chloride Urine 0.9918 2.4216 15-250
The plasma potassium linearity study resulted in a polynomial regression in which the 3rd
order polynomial regression was considered significant. Therefore, the deviation of the
results from the 3rd order linear regression were compared against the best fit line. The
plasma potassium polynomial regression results are summarized in the following table:
Sample Best line P r e d i c t e d A b s o l u t e R elative
regression 3 r d o r d e r d i f f e r e n c e % difference
mmol/L mmol/L
1 0.948 0.993 0.045 4.7418
2 2.1783 2.1786 0.0003 0.0158
3 3.4086 3.386 -0.0226 -0.6628
4 4.6388 4.6101 -0.0288 -0.62
5 5.8691 5.8461 -0.0231 -0.3928
6 7.0994 7.089 -0.0104 -0.1461
7 8.3297 8.334 0.0044 0.0526
8 9.5599 9.5763 0.0163 0.1706
9 10.7902 10.8107 0.0205 0.902
10 12.0205 12.0326 0.0121 0.1007
11 13.2508 13.2369 -0.0138 -.1044
8

[Table 1 on page 8]
	Analyte			Matrix			Slope			Intercept			Range Tested	
													(mmol/L)	
Sodium			Serum			0.9804			2.7508			70-190		
Sodium			Plasma			1.0076			0.8378			70-185		
Sodium			Urine			1.0100			2.1287			15-250		
Potassium			Serum			0.9978			0.0437			1.5-11.0		
Potassium			Urine			0.9781			0.3260			3.0-110		
Chloride			Serum			1.0690			1.1321			60-145		
Chloride			Plasma			0.9788			3.4818			60-140		
Chloride			Urine			0.9918			2.4216			15-250		

[Table 2 on page 8]
														
	Sample			Best line			P r e d i c t e d			A b s o l u t e			R elative	
				regression			3 r d o r d e r			d i f f e r e n c e			% difference	
				mmol/L			mmol/L							
1			0.948			0.993			0.045			4.7418		
2			2.1783			2.1786			0.0003			0.0158		
3			3.4086			3.386			-0.0226			-0.6628		
4			4.6388			4.6101			-0.0288			-0.62		
5			5.8691			5.8461			-0.0231			-0.3928		
6			7.0994			7.089			-0.0104			-0.1461		
7			8.3297			8.334			0.0044			0.0526		
8			9.5599			9.5763			0.0163			0.1706		
9			10.7902			10.8107			0.0205			0.902		
10			12.0205			12.0326			0.0121			0.1007		
11			13.2508			13.2369			-0.0138			-.1044		

--- Page 9 ---
Urine auto-rerun dilution validation study:
An auto-rerun validation study was performed to evaluate the accuracy of the analyzer’s
auto dilution function to obtain results for urine samples with analyte concentrations
above the measuring range. Three samples (low, middle, and high) of the extended range
were used for the study. Each sample was manually diluted with 1:1.5 ratio using a
sample volume of 9.7 µL. Each sample was measured in triplicate on one cobas c 501
analyzer which uses a decreased sample volume dilution method. The results from the
manually diluted urine samples were compared to the results from the auto-rerun dilution
samples. The study protocol and pre-determined acceptance criteria were reviewed and
found to be adequate. The results of the auto-rerun study support the sponsor’s extended
measuring range claims for urine sodium (250 to 375 mmol/L ), urine potassium (100 to
150 mmol/L) and urine chloride (100 to 150 mmol/L ) samples.
The results of the linearity studies and the auto-rerun validation for urine samples support
the sponsor’s following claimed measuring ranges:
Serum Sodium: 80-180 mmol/L
Serum Potassium: 1.5-10.0 mmol/L
Serum Chloride: 60-140 mmol/L
Urine Sodium: 20-250 mmol/L (auto-dilution extended range: 251-375 mmol/L)
Urine Potassium: 3-100 mmol/L (auto-dilution extended range: 101-150 mmol/L)
Urine Chloride: 20-250 mmol/L (auto-dilution extended range: 251-375 mmol/L)
c. Traceability, Stability, Expected values (controls, calibrators, or methods):
Traceability:
The ISE Standard Low (S1) and ISE Standard High (S2 and S3) are standardized
against primary calibrators prepared gravimetrically from purified salts. The Sodium
Chloride, Potassium Dihydrogenphosphate and Sodium Hydrogencarbonate salts with
a minimum of 99.5% purity and USP grade were used.
Stability:
Shelf life: The ISE Standard Low (S1) and ISE Standard High (S2 and S3) are stable
at 15-25˚ C for 60 months or until the expiration date listed on the labeling.
Open vial: The ISE standards are intended to be used immediately after opening and
are intended to be used for one calibration only.
Value assignment:
The ISE standard low is prepared by dissolving 1870.32 g of Sodium Chloride,
163.30 g of Potassium dihydrogenphosphate, and 1344.00 g of Sodium
hydrogencarbonate in 400.00 kg of water.
9

--- Page 10 ---
The ISE standard high is prepared by dissolving 2805.50 g of Sodium Chloride,
381.05 g of Potassium dihydrogenphosphate, and 1344.00 g of Sodium
hydrogencarbonate in 400.00 kg of water.
All standard solutions are checked against the reference methods and must meet the
internal specifications before released. The expected values are as follows:
S1: ISE Standard Low (120 mmol/L Na+, 3 mmol/L K+, 80 mmol/L Cl-)
S2: ISE Standard High (160 mmol/L Na+, 7 mmol/L K+, 120 mmol/L Cl-)
S3: ISE Standard High (160 mmol/L Na+, 7 mmol/L K+, 120 mmol/L Cl-)
All 3 standards are used for the full calibration, S3 is considered as a compensator. The
slope of the calibration curve is calculated from Standards 1 and 2; the ISE compensation
will affect the intercept, not the slope.
d. Detection limit:
Studies were carried out in accordance with CLSI Guidance Document EP17-A for
Sodium, Potassium and Chloride analytes. For determination of LoB one analyte free
sample was measured in 5 replicates, 6 runs, 3 days, on 2 cobas c 501 analyzers. Total of
60 measurements were obtained per analyzer. For determination of LoD, five samples
(one replicate) with low-analyte concentration were measured in 6 runs for 3 days on 2
cobas c 501 analyzer modules. In total 60 measurements were obtained per analyzer. For
LoQ studies a low level sample set was prepared by diluting 3 human urine and serum
samples with an analyte free diluent (ISE Diluent). The low level sample set was tested in
single replicate for 3 days in 2 runs per day on two cobas c 501 analyzers. LoQ is defined
as the concentration where total error is less than 20%. Results from the detection limit
studies are summarized in the table below:
Claimed
LoB LoD LOQ
measuring range
(mmol/L) (mmol/L) (mmol/L)
(mmol/L)
Sodium (serum)
3.9 5.7 9.7 80-180
Potassium
0.17 0.2 0.3 1.5-10
(serum)
Chloride
3.4 4.7 6.7 60-140
(serum)
Sodium
3.9 5.7 11.4 20-375
(urine)
10

[Table 1 on page 10]
				Claimed
	LoB	LoD	LOQ	
				measuring range
	(mmol/L)	(mmol/L)	(mmol/L)	
				(mmol/L)
				
Sodium (serum)	3.9	5.7	9.7	80-180
Potassium
(serum)	0.17	0.2	0.3	1.5-10
Chloride
(serum)	3.4	4.7	6.7	60-140
Sodium
(urine)	3.9	5.7	11.4	20-375

--- Page 11 ---
Potassium
0.17 0.2 0.2 3-150
(urine)
Chloride
3.4 4.7 8.8 20-375
(urine)
e. Analytical specificity:
Drug interference: Serum and urine sample pools with low and high concentrations of
each analyte were spiked with drugs and concentrations listed below. The analyte
concentrations of the spiked aliquots were tested in triplicate and the mean of the
triplicate determinations is compared to the analyte concentration of the reference
sample which contains no drugs. The sponsor’s definition of significant interference
is ≥±10% of the initial value.
Approximate Concentration of Analytes tested for drug interference
Analyte Matrix Low High
(mmol/L) (mmol/L)
Sodium Serum 123 150
Sodium Urine 60 215
Potassium Serum 3.80 6.50
Potassium Urine 20 95
Chloride Serum 95 105
Chloride Urine 105 225
There was no significant interference for serum sodium, potassium, and chloride
when these analytes and interferents were tested in the concentrations indicated
below.
Drug Interference for Serum Sodium, Potassium and Chloride
Concentration at which
no significant interference
Drug was observed (mg/dL)
Acetylcystein 150
Ampicillin-Na 1000
Ascorbic acid 300
Cyclosporin 5
Na-Cefoxitin 2500
Heparin 5000 U
Intralipid 10000
Levodopa 20
Methyldopa 20
Metronidazole 200
Phenylbutazone 400
11

[Table 1 on page 11]
Potassium
(urine)	0.17	0.2	0.2	3-150
Chloride
(urine)	3.4	4.7	8.8	20-375

[Table 2 on page 11]
	Analyte			Matrix			Low			High	
							(mmol/L)			(mmol/L)	
Sodium			Serum			123			150		
Sodium			Urine			60			215		
Potassium			Serum			3.80			6.50		
Potassium			Urine			20			95		
Chloride			Serum			95			105		
Chloride			Urine			105			225		

[Table 3 on page 11]
				Concentration at which	
	Drug			no significant interference	
				was observed (mg/dL)	
Acetylcystein			150		
Ampicillin-Na			1000		
Ascorbic acid			300		
Cyclosporin			5		
Na-Cefoxitin			2500		
Heparin			5000 U		
Intralipid			10000		
Levodopa			20		
Methyldopa			20		
Metronidazole			200		
Phenylbutazone			400		

--- Page 12 ---
Doxycyclin 50
Acetysalicylic acid 1000
Rifampicin 60
Acetaminophen 200
Ibuprofen 500
Theophylline 100
There was no significant interference for urine sodium, potassium, and chloride when
these analytes and interferents were tested in the concentrations indicated below.
Drug Interference for Urine Sodium, Potassium and Chloride
Concentration at which
no significant interference was
Drug observed (mg/dL)
Acetaminophen 3000
N-Acetyl cystein 10
Salicyurlic acid 6000
Ascorbic acid 4000
Na-Cefoxitin 120000
Gentamycin Sulfate 400
Ibuprofen 4000
Levodopa 1000
Methyldopa 2000
Metronidazole 200
Ofloxacine 900
Phenylbutazone 300
Tetracycline 300
Rifampicin 60
Endogenous Interference
Serum sample pools with low and high concentrations of each analyte were spiked
with conjugated and unconjugated bilirubin, hemoglobin, and intralipids in the
concentrations listed below. Urine sample pools with low and high concentrations of
each analyte were spiked with conjugated bilirubin and hemoglobin. The analyte
concentrations of the spiked aliquots were tested in triplicate and the mean of the
triplicate determinations is compared to the analyte concentration of the reference
sample which contains no endogenous substances. The sponsor’s definition of
significant interference is ≥±10% of the initial value.
12

[Table 1 on page 12]
Doxycyclin	50
Acetysalicylic acid	1000
Rifampicin	60
Acetaminophen	200
Ibuprofen	500
Theophylline	100

[Table 2 on page 12]
				Concentration at which	
	Drug			no significant interference was	
				observed (mg/dL)	
Acetaminophen			3000		
N-Acetyl cystein			10		
Salicyurlic acid			6000		
Ascorbic acid			4000		
Na-Cefoxitin			120000		
Gentamycin Sulfate			400		
Ibuprofen			4000		
Levodopa			1000		
Methyldopa			2000		
Metronidazole			200		
Ofloxacine			900		
Phenylbutazone			300		
Tetracycline			300		
Rifampicin			60		

--- Page 13 ---
Serum and Urine Sodium, Potassium and Chloride Concentrations Tested
Analyte Analyte
Concentration C oncentration
Analyte Low High (mmol/L)
(mmol/L)
Interferent Serum
Unconjugated Sodium 126 147
bilirubin Potassium 2.83 5.99
Chloride 92 111
Conjugated Sodium 125 148
bilirubin Potassium 2.98 6.29
Chloride 95 115
Hemoglobin Sodium 120 141
Potassium 2.78 5.89
Chloride 93 111
Lipemia Sodium 113 133
Potassium 2.65 6.62
Chloride 84 101
Interferent Urine
Conjugated Sodium 39 210
bilirubin Potassium 18.8 65.6
Chloride 46 96
Hemoglobin Sodium 35 198
Potassium 18 63
Chloride 47 190
Results Summary:
Serum: Concentration of interferent at which no significant interference was
observed.
Interferent Sodium Potassium Chloride
Hemoglobin 1000 mg/dL Avoid hemolyzed 1000 mg/dL
specimens*
Conjugated 60 mg/dL 60 mg/dL 60 mg/dL
Bilirubin
Unconjugated 60 mg/dL 60 mg/dL 60 mg/dL
Bilirubin
Lipemia 2000 mg/dL 2000 mg/dL 2000 mg/dL
* Hemolysis interferes with potassium determinations.
Sponsor has the following limitation in the labeling:
“Hemoglobin levels higher than 90 mg/dL increase the apparent potassium
concentrations significantly (appropriately H index 90). Potassium concentration in
13

[Table 1 on page 13]
							Analyte			Analyte	
				Analyte			Concentration			C oncentration	
							Low			High (mmol/L)	
							(mmol/L)				
	Interferent			Serum							
Unconjugated
bilirubin			Sodium			126			147		
			Potassium			2.83			5.99		
			Chloride			92			111		
Conjugated
bilirubin			Sodium			125			148		
			Potassium			2.98			6.29		
			Chloride			95			115		
Hemoglobin			Sodium			120			141		
			Potassium			2.78			5.89		
			Chloride			93			111		
Lipemia			Sodium			113			133		
			Potassium			2.65			6.62		
			Chloride			84			101		
	Interferent			Urine							
Conjugated
bilirubin			Sodium			39			210		
			Potassium			18.8			65.6		
			Chloride			46			96		
Hemoglobin			Sodium			35			198		
			Potassium			18			63		
			Chloride			47			190		

[Table 2 on page 13]
I	nterferent			Sodium			Potassium			Chloride	
Hemoglobin			1000 mg/dL			Avoid hemolyzed
specimens*			1000 mg/dL		
Conjugated
Bilirubin			60 mg/dL			60 mg/dL			60 mg/dL		
Unconjugated
Bilirubin			60 mg/dL			60 mg/dL			60 mg/dL		
Lipemia			2000 mg/dL			2000 mg/dL			2000 mg/dL		

--- Page 14 ---
erythrocytes is 25 times higher than in normal plasma. The level of interference may
be variable depending on the exact content of erythrocytes. Avoid hemolyzed
specimens”
Urine: Concentration of interferent at which no significant interference was observed.
Interferent Sodium Potassium Chloride
Hemoglobin 1000 mg/dL 100 mg/dL 1000 mg/dL
Conjugated 60 mg/dL 60 mg/dL 60 mg/dL
Bilirubin
f. Assay cut-off:
Not applicable
2. Comparison studies:
a. Method comparison with predicate device:
Sodium, potassium and chloride values for human plasma and urine samples were
obtained on the Roche/Hitachi cobas c 501 analyzers and where compared to those
determined on the corresponding reference method and with the Roche/Hitachi 912.
The reference methods used were: Flame Photometer IL 943 for Sodium and
Potassium and the Chloride Analyzer 926S for Chloride. No more than 20% of the
samples were either spiked or diluted to cover the measuring range. In addition, the
samples were tested in singlicate on one cobas 501 with the candidate device and one
c 501 with the predicate device. The results were calculated using Passing/Bablok
Linear regression. The method comparison result summary is shown in the tables
below:
Serum Sodium Method Comparison:
Flame Photometer vs candidate device
n Range Regression Passing-Bablok r
mmol/L
103 87-178 y=1.000x+0.300 0.999
Serum Sodium Method Comparison:
Predicate device vs candidate device
n Range Regression Passing-Bablok r
mmol/L
103 87-176 y=1.014x-1.176 1.000
Urine Sodium Method Comparison:
Flame Photometer vs candidate device
n Range Regression Passing-Bablok r
mmol/L
100 24-250 y=0.964+4.032 1.000
14

[Table 1 on page 14]
	Interferent			Sodium			Potassium			Chloride	
Hemoglobin			1000 mg/dL			100 mg/dL			1000 mg/dL		
Conjugated
Bilirubin			60 mg/dL			60 mg/dL			60 mg/dL		

[Table 2 on page 14]
n	Range
mmol/L	Regression Passing-Bablok	r
103	87-178	y=1.000x+0.300	0.999

[Table 3 on page 14]
n	Range
mmol/L	Regression Passing-Bablok	r
103	87-176	y=1.014x-1.176	1.000

[Table 4 on page 14]
n	Range
mmol/L	Regression Passing-Bablok	r
100	24-250	y=0.964+4.032	1.000

--- Page 15 ---
Urine Sodium Method Comparison:
Predicate device vs candidate device
n Range Regression Passing-Bablok r
mmol/L
100 25-245 y=0.995x+0.687 1.000
Serum Potassium Method Comparison:
Flame Photometer vs candidate device
n Range Regression Passing-Bablok r
mmol/L
106 1.59-9.56 y=1.007x-0.190 1.00
Serum Potassium Method Comparison:
Predicate device vs candidate device
n Range Regression Passing-Bablok r
mmol/L
106 1.52-9.49 y=1.006x+0.024 1.00
Urine Potassium Method Comparison:
Flame Photometer vs candidate device
n Range Regression Passing-Bablok r
mmol/L
105 4.00-97.2 y=1.018x-0.397 1.00
Urine Potassium Method Comparison:
Predicate device vs candidate device
n Range Regression Passing-Bablok r
mmol/L
105 4.05-97.4 y=0.997x+0.062 0.999
Serum Chloride Method Comparison:
Coulmetry vs candidate device
n Range Regression Passing-Bablok r
mmol/L
105 62-136 y=1.033x-1.800 0.998
Serum Chloride Method Comparison:
Predicate device vs candidate device
n Range Regression Passing-Bablok r
mmol/L
105 61-138 y=1.000x +0.50 0.999
15

[Table 1 on page 15]
n	Range
mmol/L	Regression Passing-Bablok	r
100	25-245	y=0.995x+0.687	1.000

[Table 2 on page 15]
n	Range
mmol/L	Regression Passing-Bablok	r
106	1.59-9.56	y=1.007x-0.190	1.00

[Table 3 on page 15]
n	Range
mmol/L	Regression Passing-Bablok	r
106	1.52-9.49	y=1.006x+0.024	1.00

[Table 4 on page 15]
n	Range
mmol/L	Regression Passing-Bablok	r
105	4.00-97.2	y=1.018x-0.397	1.00

[Table 5 on page 15]
n	Range
mmol/L	Regression Passing-Bablok	r
105	4.05-97.4	y=0.997x+0.062	0.999

[Table 6 on page 15]
n	Range
mmol/L	Regression Passing-Bablok	r
105	62-136	y=1.033x-1.800	0.998

[Table 7 on page 15]
n	Range
mmol/L	Regression Passing-Bablok	r
105	61-138	y=1.000x +0.50	0.999

--- Page 16 ---
Urine Chloride Method Comparison:
Coulometry vs candidate device
n Range Regression Passing-Bablok r
mmol/L
105 22-248 y=1.020x -1.70 0.999
Urine Chloride Method Comparison:
Predicate device vs candidate device
n Range Regression Passing-Bablok r
mmol/L
105 21-250 y=0.989x+0.669 1.000
b. Matrix comparison:
A matrix comparison study was performed to compare the recovery of the proposed
anticoagulated sample type, lithium heparin, to the recovery of serum sample type.
Thirty matched serum (SST) and lithium heparin samples were run in singlet on one
cobas c 501 analyzer, at one site, with one lot of ISE diluent. Testing was performed
during one day. Passing/Bablok linear regression analysis was used to evaluate the
mean data and the result summary is shown below:
Serum vs. Lithium Heparin Plasma
Analyte n Range Slope Intercept Correlation
mmol/L Coefficient (r)
Sodium 30 80-174 1.003 -0.659 1.000
Potassium 30 1.77-8.98 0.9960 0.023 0.995
Chloride 30 64-136 1.009 -0.754 0.999
Sponsor concluded that lithium heparin is an acceptable anti-coagulant to be used with
the candidate device.
3. Clinical studies:
a. Clinical Sensitivity:
Not applicable
b. Clinical specificity:
Not applicable
c. Other clinical supportive data (when a. and b. are not applicable):
Not applicable
4. Clinical cut-off:
Not applicable
16

[Table 1 on page 16]
n	Range
mmol/L	Regression Passing-Bablok	r
105	22-248	y=1.020x -1.70	0.999

[Table 2 on page 16]
n	Range
mmol/L	Regression Passing-Bablok	r
105	21-250	y=0.989x+0.669	1.000

[Table 3 on page 16]
	Analyte			n			Range			Slope			Intercept			Correlation	
							mmol/L									Coefficient (r)	
Sodium			30			80-174			1.003			-0.659			1.000		
Potassium			30			1.77-8.98			0.9960			0.023			0.995		
Chloride			30			64-136			1.009			-0.754			0.999		

--- Page 17 ---
5. Expected values/Reference range:
The expected values for adult based serum, plasma and 24-hour urine out put are cited
from the literature1:
Serum (Adults)
Sodium: 136-145 mmol/L
Potassium: 3.5-5.1 mmol/L
Chloride: 98-107 mmol/L
Plasma (Adults)
Sodium: 136-145 mmol/L
Potassium: 3.4-4.5 mmol/L
Chloride: 98-107 mmol/L
Urine, 24 hour (Adults)
Sodium: 40-220 mmol/24h
Potassium: 25-125 mmol/24h
Chloride: 110-250 mmol/24h
References:
1. Tietz Fundamentals of Clinical Chemistry, Fifth Edition, Edited by Carl A. Burlis and
Edward R. Ashwood, W.B. Saunders Company, 2001:970, 1004,1009 (ISBN 0-7216-
8634-6.
N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.
O. Conclusion:
The submitted information in this premarket notification is complete and supports a
substantial equivalence decision.
17